High Uric Acid Without Gout: Should You Worry?

In our entries on uric acid (blood test) and on gout, we describe the mechanism by which excess uric acid crystallizes as sodium urate in the joints, triggering the acute inflammation responsible for the classic, very painful gout attack. The key, often surprising fact: most people with elevated uric acid never experience a gout attack in their entire life. Crystallization itself and its clinical manifestation as an attack are two different things, depending on additional factors — not just the uric acid level alone.

This article focuses specifically on that narrower situation — an elevated result with no attack in the past — assuming the reader already knows what uric acid is and how a gout attack unfolds, which we cover more broadly in the entries above.

Uric acid forms as a breakdown product of purines — both those from diet and those released through the body's natural cell turnover — in a reaction catalyzed by the enzyme xanthine oxidase. In humans, unlike most other mammals, there's no further enzyme (uricase) to break uric acid down into more soluble products, which partly explains why we're evolutionarily more prone to its excessive buildup in the blood. Any excess that isn't excreted by the kidneys begins to crystallize as sodium urate once it exceeds the solubility threshold, usually around 6.8 mg/dL.

Crystallization in the joints alone, however, isn't the same as a gout attack — a second step is needed: recognition of the crystals by immune cells (macrophages) and activation of the NLRP3 inflammasome, which releases the pro-inflammatory cytokine interleukin-1 beta, triggering the actual, painful inflammatory attack. Whether and when this second step happens depends on individual factors that aren't fully understood — which explains why some people with long-standing, markedly elevated hyperuricemia never have an attack, while others with a more mildly elevated level experience one relatively quickly.

A second, more important layer of nuance for this article concerns whether elevated uric acid itself increases cardiovascular and kidney risk, or whether it's simply a marker reflecting other, underlying metabolic problems. Observational studies consistently show an association between asymptomatic hyperuricemia and elevated risk of hypertension, chronic kidney disease, and cardiovascular events, with the proposed mechanism involving vascular endothelial dysfunction, oxidative stress, and local inflammation triggered by uric acid itself.

The trouble is that hyperuricemia strongly co-occurs with other risk factors — obesity, insulin resistance, excess fructose and alcohol intake, and impaired kidney function itself, which on one hand raises uric acid (because the kidneys excrete it less efficiently) and on the other is itself a cardiovascular risk factor. This phenomenon, known as reverse causation or confounding, makes it hard to say definitively whether uric acid itself causes the increased risk, or is merely a convenient-to-measure reflection of a broader metabolic disturbance that would warrant attention regardless of the uric acid result itself.

For years there was a hypothesis that lowering uric acid with medication in asymptomatic people could prevent kidney disease progression and cardiovascular events. Results from the large CARES trial, which evaluated febuxostat in gout patients with elevated cardiovascular risk, along with subsequent meta-analyses, haven't clearly confirmed such a benefit in people without symptoms — leading most current guidelines to recommend against starting preventive drug treatment based solely on an elevated result with no clinical symptoms at all.

Exceptions where treating asymptomatic hyperuricemia is sometimes justified include very high values with a real risk of acute kidney injury (for example, before intensive chemotherapy, where massive cancer cell breakdown releases huge amounts of purines — so-called tumor lysis syndrome), recurrent uric-acid-related kidney stones, and individually assessed cases of coexisting, progressive chronic kidney disease, where the decision should be made by a nephrologist after reviewing the full clinical picture, not based on the number alone.

This distinction has practical significance: instead of focusing solely on 'should I take medication,' it's worth asking more broadly — does this result, together with other parameters (body weight, lipid profile, glucose, kidney function), add up to a picture of metabolic syndrome that deserves attention regardless of the uric acid level itself?

Elevated uric acid without a gout attack presents a dilemma that's fairly rare in medicine: neither fully ignoring the result nor automatically treating it is fully justified by current evidence. This is a situation calling for nuance — treating the result as a starting point for a broader conversation about lifestyle and metabolic factors, rather than as a final diagnosis requiring immediate drug intervention.